Abdulhamit Yildirim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Abdulhamit Yildirim has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- İsMail Abidin
Department of Biophysics, Faculty of Medicine, Karadeniz Technical University, Trabzon, Türkiye
3 shared publications - Osman Aktaş
Department of Physiology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
3 shared publications - Selcen Aydin-Abidin
Department of Biophysics, Faculty of Medicine, Karadeniz Technical University, Trabzon, Türkiye
3 shared publications - Zafer Sahin
Department of Physiology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
3 shared publications - Ömer Faruk Kalkan
Department of Physiology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
3 shared publications - Ali Faruk Özyaşar
Department of Anatomy, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
2 shared publications
Latest Publications
- 12 November 2025
- Published by Springer Nature in Biologia Futura
- Vol. 77 (1) , 155-164
Central administration of asprosin reduces baseline brain activity but does not attenuate 4-AP-induced epileptiform discharges: an in vivo electrophysiological study
In the current study, we investigated the effects of central asprosin administration on baseline brain activity and 4-aminopyridine (4-AP) induced epileptiform activity. Additionally, we examined the effects of asprosin on electrocorticography (ECoG) band powers. Forty-two male Wistar rats were divided into six groups as follows: sham, 4-AP (2.5 mg/kg i.p.), asprosin 20 nmol (i.c.v.), asprosin 50 nmol (i.c.v.), asprosin 50 nmol (i.c.v.) posttreatment, and asprosin 50 nmol (i.c.v.) pre-treatment. Recordings lasting 60–70 min were conducted for all groups under ketamine/xylazine (90/10 mg/kg) anesthesia. In the posttreatment group, asprosin was injected 20 min after the induction of epileptiform activity. In the pre-treatment group, asprosin was injected after baseline recordings, and following a 20-min pre-treatment period, 4-AP was administered. 4-AP alone induced epileptiform activity in all animals, peaking at approximately the 30th minute. Asprosin significantly reduced ECoG power at doses of 20 nmol and 50 nmol. Furthermore, both doses of asprosin reduced alpha, beta, delta, theta, and gamma band activity in ECoG recordings at various time points. However, asprosin pre- and posttreatment had no significant effect on 4-AP-induced epileptiform activity. These findings suggest that asprosin modulates cortical excitability under physiological conditions but is ineffective in attenuating induced epileptiform activity.
- 12 November 2025
- Published by Springer Nature in Biologia Futura
- Vol. 77 (1) , 155-164
Central administration of asprosin reduces baseline brain activity but does not attenuate 4-AP-induced epileptiform discharges: an in vivo electrophysiological study
In the current study, we investigated the effects of central asprosin administration on baseline brain activity and 4-aminopyridine (4-AP) induced epileptiform activity. Additionally, we examined the effects of asprosin on electrocorticography (ECoG) band powers. Forty-two male Wistar rats were divided into six groups as follows: sham, 4-AP (2.5 mg/kg i.p.), asprosin 20 nmol (i.c.v.), asprosin 50 nmol (i.c.v.), asprosin 50 nmol (i.c.v.) posttreatment, and asprosin 50 nmol (i.c.v.) pre-treatment. Recordings lasting 60–70 min were conducted for all groups under ketamine/xylazine (90/10 mg/kg) anesthesia. In the posttreatment group, asprosin was injected 20 min after the induction of epileptiform activity. In the pre-treatment group, asprosin was injected after baseline recordings, and following a 20-min pre-treatment period, 4-AP was administered. 4-AP alone induced epileptiform activity in all animals, peaking at approximately the 30th minute. Asprosin significantly reduced ECoG power at doses of 20 nmol and 50 nmol. Furthermore, both doses of asprosin reduced alpha, beta, delta, theta, and gamma band activity in ECoG recordings at various time points. However, asprosin pre- and posttreatment had no significant effect on 4-AP-induced epileptiform activity. These findings suggest that asprosin modulates cortical excitability under physiological conditions but is ineffective in attenuating induced epileptiform activity.
- 30 October 2025
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (6) , 1-10
3-Carene Modulates Baseline Brain Electrical Activity Without Suppressing 4-Aminopyridine-Induced Seizure Events: An In Vivo and In Vitro Electrophysiological Study
In the current study, we investigated the effects of 3-carene administration on basal brain activity and 4-aminopyridine (4-AP) induced epileptiform activity. Additionally, we examined the effects of asprosin on ECoG band powers. Thirty-five male Wistar rats were divided into five groups as follows: control (DMSO), 4-AP (2.5 mg/kg i.p.), 3-carene 10 mg/kg (i.p), 3-carene 50 mg/kg (i.p), 3-carene 50 mg/kg (i.p) post-treatment. Recordings lasting 60–70 min were conducted for all groups under ketamine/xylazine (90/10 mg/kg) anesthesia. Furthermore, we used thick acute horizontal hippocampal slices obtained from 30‑ to 35‑day‑old rats for in vitro experiments. Extracellular field potential recordings were evaluated in the CA1 region of the hippocampus. In vivo recordings revealed that intraperitoneal administration of 3-carene (10 mg/kg and 50 mg/kg) significantly suppressed basal brain activity across delta, theta, alpha, and beta bands. However, 3-carene failed to reduce epileptiform discharges induced by 4-AP. Complementary in vitro experiments using hippocampal and entorhinal cortex slices further confirmed the lack of anticonvulsant effect, as 3-carene did not alter the frequency or duration of 4-AP-induced ictal or interictal events. These findings suggest that while 3-carene modulates resting-state cortical oscillations, it lacks efficacy in suppressing seizure-like activity. The results highlight its potential as a neuromodulatory agent rather than a standalone anticonvulsant.
- 30 October 2025
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (6) , 1-10
3-Carene Modulates Baseline Brain Electrical Activity Without Suppressing 4-Aminopyridine-Induced Seizure Events: An In Vivo and In Vitro Electrophysiological Study
In the current study, we investigated the effects of 3-carene administration on basal brain activity and 4-aminopyridine (4-AP) induced epileptiform activity. Additionally, we examined the effects of asprosin on ECoG band powers. Thirty-five male Wistar rats were divided into five groups as follows: control (DMSO), 4-AP (2.5 mg/kg i.p.), 3-carene 10 mg/kg (i.p), 3-carene 50 mg/kg (i.p), 3-carene 50 mg/kg (i.p) post-treatment. Recordings lasting 60–70 min were conducted for all groups under ketamine/xylazine (90/10 mg/kg) anesthesia. Furthermore, we used thick acute horizontal hippocampal slices obtained from 30‑ to 35‑day‑old rats for in vitro experiments. Extracellular field potential recordings were evaluated in the CA1 region of the hippocampus. In vivo recordings revealed that intraperitoneal administration of 3-carene (10 mg/kg and 50 mg/kg) significantly suppressed basal brain activity across delta, theta, alpha, and beta bands. However, 3-carene failed to reduce epileptiform discharges induced by 4-AP. Complementary in vitro experiments using hippocampal and entorhinal cortex slices further confirmed the lack of anticonvulsant effect, as 3-carene did not alter the frequency or duration of 4-AP-induced ictal or interictal events. These findings suggest that while 3-carene modulates resting-state cortical oscillations, it lacks efficacy in suppressing seizure-like activity. The results highlight its potential as a neuromodulatory agent rather than a standalone anticonvulsant.
- 21 January 2025
- Published by Taylor & Francis in Neurological Research
- Vol. 47 (2) , 139-146
Central administration of p234, kisspeptin antagonist, but not kisspeptin-10, reduces the power of epileptiform activity and slow EEG waves in male rats
We aimed to investigate the effects of central kisspeptin-10 and p234 administration on basal brain activity and epilepsy-like conditions induced by 4-aminopyridine (4-AP), as well as their roles in the electrocorticogram (ECoG) power spectrum and EEG waves. Thirty-five male Wistar rats were divided into five groups: sham,4-AP (2.5 mg/kg i.p.), kisspeptin-10 post-treatment (200 pmoli.c.v.), p234 post-treatment (1 nmol i.c.v.), and p234 pre-treatment (1 nmol i.c.v.). We performed 70 minutes of recordings (10 min baseline) for all groups under ketamine/xylazine (90/10 mg/kg) anesthesia. In the post-treatment groups, kisspeptin-10 or p234 injections were administered 20 minutes after epilepsy induction. In the pre-treatment group, p234 was injected after baseline recordings. Following a 20-minute pre-treatment period, 4-AP was administered. 4-AP alone induced epileptiform activity in all animals, reaching apeak after 30 minutes. Neither kisspeptin-10 nor p234 post-treatment affected 4-AP-induced epileptiform activity (p > 0.05). However, p234 pre-treatment reduced epileptiform activity (p < 0.05). Additionally, kisspeptin-10 did not alter the spectral analysis of the EEG bands or the power of the ECoG (p > 0.05). In contrast, p234 reduced the power of the ECoG and the slow bands (delta and theta) (p < 0.05). We conclude that p234 pre-treatment has an inhibitory effect on neuronal excitability and epileptiform activity in the neocortex.
- 21 January 2025
- Published by Taylor & Francis in Neurological Research
- Vol. 47 (2) , 139-146
Central administration of p234, kisspeptin antagonist, but not kisspeptin-10, reduces the power of epileptiform activity and slow EEG waves in male rats
We aimed to investigate the effects of central kisspeptin-10 and p234 administration on basal brain activity and epilepsy-like conditions induced by 4-aminopyridine (4-AP), as well as their roles in the electrocorticogram (ECoG) power spectrum and EEG waves. Thirty-five male Wistar rats were divided into five groups: sham,4-AP (2.5 mg/kg i.p.), kisspeptin-10 post-treatment (200 pmoli.c.v.), p234 post-treatment (1 nmol i.c.v.), and p234 pre-treatment (1 nmol i.c.v.). We performed 70 minutes of recordings (10 min baseline) for all groups under ketamine/xylazine (90/10 mg/kg) anesthesia. In the post-treatment groups, kisspeptin-10 or p234 injections were administered 20 minutes after epilepsy induction. In the pre-treatment group, p234 was injected after baseline recordings. Following a 20-minute pre-treatment period, 4-AP was administered. 4-AP alone induced epileptiform activity in all animals, reaching apeak after 30 minutes. Neither kisspeptin-10 nor p234 post-treatment affected 4-AP-induced epileptiform activity (p > 0.05). However, p234 pre-treatment reduced epileptiform activity (p < 0.05). Additionally, kisspeptin-10 did not alter the spectral analysis of the EEG bands or the power of the ECoG (p > 0.05). In contrast, p234 reduced the power of the ECoG and the slow bands (delta and theta) (p < 0.05). We conclude that p234 pre-treatment has an inhibitory effect on neuronal excitability and epileptiform activity in the neocortex.
- 3 October 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (7) , e2893-e2894
Radiographic and lithotripter parameters to predict ESWL success for renal and ureteral stones
- 3 October 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (7) , e2893-e2894
Radiographic and lithotripter parameters to predict ESWL success for renal and ureteral stones